216 related articles for article (PubMed ID: 37188783)
1. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F; Patil V; Yefet LS; Singh O; Liu J; Dang RMA; Yamaguchi TN; Daras M; Cloughesy TF; Colman H; Kumthekar PU; Chen CC; Aiken R; Groves MD; Ong SS; Ramakrishna R; Vogelbaum MA; Khagi S; Kaley T; Melear JM; Peereboom DM; Rodriguez A; Yankelevich M; Nair SG; Puduvalli VK; Aldape K; Gao A; López-Janeiro Á; de Andrea CE; Alonso MM; Boutros P; Robbins J; Mason WP; Sonabend AM; Stupp R; Fueyo J; Gomez-Manzano C; Lang FF; Zadeh G
Nat Med; 2023 Jun; 29(6):1370-1378. PubMed ID: 37188783
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J
J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077
[TBL] [Abstract][Full Text] [Related]
3. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
5. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
Guan J; Sun K; Guerrero CA; Zheng J; Xu Y; Mathur S; Teh BS; Farach A; Zhang J; Butler E; Pan PY; Zsigmond E; Mei Z; Mejia J; Chen SH; Chang JC; Bernicker EH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1531-1540. PubMed ID: 37625523
[TBL] [Abstract][Full Text] [Related]
7. DNX-2401: an investigational drug for the treatment of recurrent glioblastoma.
Philbrick B; Adamson DC
Expert Opin Investig Drugs; 2019 Dec; 28(12):1041-1049. PubMed ID: 31726894
[No Abstract] [Full Text] [Related]
8. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
[TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Gállego Pérez-Larraya J; Garcia-Moure M; Labiano S; Patiño-García A; Dobbs J; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; Puigdelloses M; Laspidea V; Astigarraga I; Lopez-Ibor B; Cruz O; Oscoz Lizarbe M; Hervas-Stubbs S; Alkorta-Aranburu G; Tamayo I; Tavira B; Hernandez-Alcoceba R; Jones C; Dharmadhikari G; Ruiz-Moreno C; Stunnenberg H; Hulleman E; van der Lugt J; Idoate MÁ; Diez-Valle R; Esparragosa Vázquez I; Villalba M; de Andrea C; Núñez-Córdoba JM; Ewald B; Robbins J; Fueyo J; Gomez-Manzano C; Lang FF; Tejada S; Alonso MM
N Engl J Med; 2022 Jun; 386(26):2471-2481. PubMed ID: 35767439
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.
Todo T; Ito H; Ino Y; Ohtsu H; Ota Y; Shibahara J; Tanaka M
Nat Med; 2022 Aug; 28(8):1630-1639. PubMed ID: 35864254
[TBL] [Abstract][Full Text] [Related]
13. The Oncolytic Adenovirus DNX-2401 Has Antitumor Activity in Glioblastoma.
Cancer Discov; 2018 Apr; 8(4):382. PubMed ID: 29475886
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
15. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
Reardon DA; Kim TM; Frenel JS; Simonelli M; Lopez J; Subramaniam DS; Siu LL; Wang H; Krishnan S; Stein K; Massard C
Cancer; 2021 May; 127(10):1620-1629. PubMed ID: 33496357
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Mahalingam D; Wilkinson GA; Eng KH; Fields P; Raber P; Moseley JL; Cheetham K; Coffey M; Nuovo G; Kalinski P; Zhang B; Arora SP; Fountzilas C
Clin Cancer Res; 2020 Jan; 26(1):71-81. PubMed ID: 31694832
[TBL] [Abstract][Full Text] [Related]
18. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Hellmann MD; Jänne PA; Opyrchal M; Hafez N; Raez LE; Gabrilovich DI; Wang F; Trepel JB; Lee MJ; Yuno A; Lee S; Brouwer S; Sankoh S; Wang L; Tamang D; Schmidt EV; Meyers ML; Ramalingam SS; Shum E; Ordentlich P
Clin Cancer Res; 2021 Feb; 27(4):1019-1028. PubMed ID: 33203644
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]